In August 2022, the European Medicines Agency granted Marketing Authorization to lenacapavir (Sunlenca), the first-in-class bi-annually dosed HIV capsid inhibitor indicated for multidrug-resistant HIV-1 infection.
This Premium deep dive into Sunlenca includes:
- the industry context
- the clinical data
- the target rationale
- the mechanism of action
- and the drug’s origins.
get free samples and a Premium trial
Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: